Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Vusolimogene oderparepvec |
| Synonyms | |
| Therapy Description |
Tudriqev (vusolimogene oderparepvec) is an engineered oncolytic type-I herpes simplex virus (HSV-1) strain that expresses a fusogenic glycoprotein (GALV-GP-R-) and GM-CSF, which potentially induces an anti-tumor immune response and tumor cell lysis (Cancer Res (2024) 84 (7_Supplement): CT003, NCI Drug Dictionary). Tudriqev (vusolimogene oderparepvec) is FDA-approved for use in combination with nivolumab for patients with unresectable advanced cutaneous melanoma who have progressed on a PD-1 inhibitor therapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Vusolimogene oderparepvec | Tudriqev | vusolimogene oderparepvec-wtpg|RP1|HSV-1 Engineered RP1 | Tudriqev (vusolimogene oderparepvec) is an engineered oncolytic type-I herpes simplex virus (HSV-1) strain that expresses a fusogenic glycoprotein (GALV-GP-R-) and GM-CSF, which potentially induces an anti-tumor immune response and tumor cell lysis (Cancer Res (2024) 84 (7_Supplement): CT003, NCI Drug Dictionary). Tudriqev (vusolimogene oderparepvec) is FDA-approved for use in combination with nivolumab for patients with unresectable advanced cutaneous melanoma who have progressed on a PD-1 inhibitor therapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06216938 | Phase I | Vusolimogene oderparepvec | RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis | Recruiting | USA | 0 |
| NCT04349436 | Phase Ib/II | Vusolimogene oderparepvec | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies (ARTACUS) | Active, not recruiting | USA | 0 |
| NCT03767348 | Phase II | Nivolumab + Vusolimogene oderparepvec Vusolimogene oderparepvec | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (IGNYTE) | Active, not recruiting | USA | GBR | FRA | ESP | DEU | 0 |
| NCT04050436 | Phase II | Cemiplimab + Vusolimogene oderparepvec Vusolimogene oderparepvec | Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) | Active, not recruiting | USA | POL | ITA | GRC | FRA | ESP | DEU | CAN | BGR | AUS | 0 |
| NCT05858229 | Phase Ib/II | Vusolimogene oderparepvec | Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. | Active, not recruiting | USA | 0 |
CKB BOOST